Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972573 | 0.98 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1USP2HPGD | |
| SCHEMBL14148977 | 0.87 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1USP2TSHR | |
| Hydrochloric Acid SCHEMBL14108563 | 0.86 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1USP2TSHR | |
| SCHEMBL395429 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1CTSLCTSB | |
| SCHEMBL394616 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1LMNACTSL | |
| SCHEMBL3399492 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1LMNACTSL | |
| SCHEMBL31252092 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1GAALMNA | |
| SCHEMBL8787175 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1HPGDTSHR | |
| SCHEMBL6843353 | 0.83 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1HPGDLMNA | |
| SCHEMBL1745955 | 0.82 | HTT (0.51) | ALDH1A1USP2HPGDGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497287-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130040965-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2231589-B1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8314128-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120088794-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101791-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2231589-A2 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076399-A2 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-4908475-A | Chemical intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1990-03-13 | — | — | US | disclosed |
| US-4810778-A | OLIGOPEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1989-03-07 | — | — | US | disclosed |
| US-4760052-A | 1,6-dicarba-vasopressin compounds | SMITHKLINE BECKMAN CORPORATION (US) | 1988-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040965-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 902/4885MAPK1 1046/4885L3MBTL1 2249/4885 |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 902/4885MAPK1 1046/4885L3MBTL1 2249/4885 |
| US-20120088794-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 902/4885MAPK1 1046/4885L3MBTL1 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.